JP5869884B2 - 細胞周期の不定期の活性化に関連する神経変性障害または疾患の治療に有用なｃｄｋ４／ｃｄｋ６阻害剤をコードする誘導性遺伝子を含有するベクター - Google Patents

細胞周期の不定期の活性化に関連する神経変性障害または疾患の治療に有用なｃｄｋ４／ｃｄｋ６阻害剤をコードする誘導性遺伝子を含有するベクター Download PDF

Info

Publication number
JP5869884B2
JP5869884B2 JP2011548607A JP2011548607A JP5869884B2 JP 5869884 B2 JP5869884 B2 JP 5869884B2 JP 2011548607 A JP2011548607 A JP 2011548607A JP 2011548607 A JP2011548607 A JP 2011548607A JP 5869884 B2 JP5869884 B2 JP 5869884B2
Authority
JP
Japan
Prior art keywords
vector
cell
expression
disease
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011548607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012516691A5 (enExample
JP2012516691A (ja
Inventor
アレント，トーマス
ユーバーハム，ウヴェ
Original Assignee
ウニベルジテート ライプチヒ
ウニベルジテート ライプチヒ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニベルジテート ライプチヒ, ウニベルジテート ライプチヒ filed Critical ウニベルジテート ライプチヒ
Publication of JP2012516691A publication Critical patent/JP2012516691A/ja
Publication of JP2012516691A5 publication Critical patent/JP2012516691A5/ja
Application granted granted Critical
Publication of JP5869884B2 publication Critical patent/JP5869884B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011548607A 2009-02-04 2010-02-04 細胞周期の不定期の活性化に関連する神経変性障害または疾患の治療に有用なｃｄｋ４／ｃｄｋ６阻害剤をコードする誘導性遺伝子を含有するベクター Expired - Fee Related JP5869884B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09001521.5 2009-02-04
EP09001521A EP2218784A1 (en) 2009-02-04 2009-02-04 Vector(s) containing an inducible gene encoding a CDK4/CD6 inhibitor useful for treating neurodegenerative disorders
PCT/EP2010/000702 WO2010089122A2 (en) 2009-02-04 2010-02-04 Vector(s) containing an inducible gene encoding a cdk4/cdk6 inhibitor useful for treating neurodegenerative disorders or diseases associated with an unscheduled activation of the cell cycle

Publications (3)

Publication Number Publication Date
JP2012516691A JP2012516691A (ja) 2012-07-26
JP2012516691A5 JP2012516691A5 (enExample) 2013-03-21
JP5869884B2 true JP5869884B2 (ja) 2016-02-24

Family

ID=40673417

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011548607A Expired - Fee Related JP5869884B2 (ja) 2009-02-04 2010-02-04 細胞周期の不定期の活性化に関連する神経変性障害または疾患の治療に有用なｃｄｋ４／ｃｄｋ６阻害剤をコードする誘導性遺伝子を含有するベクター

Country Status (8)

Country Link
US (2) US20120004277A1 (enExample)
EP (2) EP2218784A1 (enExample)
JP (1) JP5869884B2 (enExample)
KR (1) KR101378353B1 (enExample)
CN (1) CN102356156A (enExample)
AU (1) AU2010211289B2 (enExample)
CA (1) CA2751531A1 (enExample)
WO (1) WO2010089122A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653324B2 (en) * 2010-06-11 2014-02-18 Fox Chase Cancer Center TetO-p16 transgenic mice
WO2012050975A2 (en) * 2010-09-29 2012-04-19 The University Of North Carolina At Chapel Hill Novel circular mammalian rna molecules and uses thereof
KR101255338B1 (ko) * 2010-12-15 2013-04-16 포항공과대학교 산학협력단 표적 세포에 대한 폴리뉴클레오티드 전달체
CN103501812A (zh) 2011-04-29 2014-01-08 西莱克塔生物科技公司 用于过敏症治疗的致耐受性合成纳米载体
CN118370823A (zh) 2013-05-03 2024-07-23 西莱克塔生物科技公司 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子
WO2016037162A1 (en) * 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector immune responses
WO2017075335A1 (en) 2015-10-28 2017-05-04 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
HUE072005T2 (hu) 2017-03-11 2025-10-28 Cartesian Therapeutics Inc Gyulladásgátlókkal és immunszupresszánst tartalmazó szintetikus nanohordozókkal történõ kombinált kezeléssel összefüggõ eljárások és készítmények
CN108319816B (zh) * 2018-02-27 2021-04-23 广州大学 一种基于基因通路识别小分子核糖核酸的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19936034C1 (de) * 1999-07-30 2001-01-25 Univ Leipzig Rekombiniertes, neuronalspezifisch aktiviertes, transkribierbares lineares DNA-Konstrukt
WO2005033277A2 (en) * 2003-09-29 2005-04-14 University Of Rochester Methods of modulating cell cycle and cell signaling pathways using biliverdin reductase
DE602005023181D1 (de) * 2004-07-21 2010-10-07 Dana Farber Cancer Inst Inc Lentivirusvektoren und deren verwendung
EP1838841A2 (en) * 2004-12-23 2007-10-03 The Ludwig Institute for Cancer Research Engineered dopamine neurons and uses thereof
US20080300202A1 (en) * 2006-05-18 2008-12-04 The State of Oregon acting by and through the State Board of Higher Education on behalf of the Subtractive transgenics
US9394538B2 (en) * 2008-05-07 2016-07-19 Shi-Lung Lin Development of universal cancer drugs and vaccines

Also Published As

Publication number Publication date
CA2751531A1 (en) 2010-08-12
WO2010089122A3 (en) 2010-12-09
AU2010211289B2 (en) 2016-12-15
WO2010089122A2 (en) 2010-08-12
EP2620447B1 (en) 2015-09-09
EP2620447A1 (en) 2013-07-31
EP2218784A1 (en) 2010-08-18
US20120004277A1 (en) 2012-01-05
AU2010211289A1 (en) 2011-09-01
CN102356156A (zh) 2012-02-15
KR101378353B1 (ko) 2014-04-10
JP2012516691A (ja) 2012-07-26
KR20110121704A (ko) 2011-11-08
US20160144054A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
JP5869884B2 (ja) 細胞周期の不定期の活性化に関連する神経変性障害または疾患の治療に有用なｃｄｋ４／ｃｄｋ６阻害剤をコードする誘導性遺伝子を含有するベクター
US8389487B2 (en) siRNA-mediated gene silencing of synuclein
CN100500854C (zh) siRNA表达系统和利用该系统制备含有被击倒的功能性基因的细胞的方法
KR20010099682A (ko) 단일가닥 ｄｎａ의 효소 합성
CN113544267A (zh) 使用CRISPR-Cas进行靶向核RNA裂解和聚腺苷酸化
KR20110128345A (ko) 생물학적 활성 ｒｎａ의 전달을 위한 조성물 및 방법
EP1499735B1 (en) Optimization of transgene expression in mammalian cells
Feng et al. A multifunctional lentiviral-based gene knockdown with concurrent rescue that controls for off-target effects of RNAi
CN116113697A (zh) 用于治疗癫痫的方法和组合物
US6838556B2 (en) Promoters for regulated gene expression
Westmark et al. Decoy mRNAs reduce β-amyloid precursor protein mRNA in neuronal cells
Friedmann‐Morvinski et al. Overexpression Models: lentiviral modeling of brain cancer
Tritz et al. Catalytic nucleic acid enzymes for the study and development of therapies in the central nervous system
TW201326195A (zh) 衍生自雞貧血病毒（ｃａｖ）ｖｐ２蛋白質的細胞核定位信號胜肽以及它們的應用
KR20110093840A (ko) 지방세포 형성의 조절을 위한 ｐｌａｃ８ 활성 억제제의 용도
Mastroyiannopoulos et al. Myotonic Dystrophy Type 1: Focus on the RNA Pathology and Therapy
WO2003070932A1 (en) Polynucleotide for target gene
Hung Combined gene therapy of siRNA and apoptosis inducing factor generated from a single transcriptional event
Michelotti et al. Promoters for regulated gene expression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140912

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151215

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160108

R150 Certificate of patent or registration of utility model

Ref document number: 5869884

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees